“We look forward to presenting the most recent data from the ORIGIN 3 trial in a late-breaking presentation during the opening plenary session of ASN Kidney Week later this week,” said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics (VERA). “We are excited to share additional data and clinical experience regarding the treatment of IgAN, which remains an area of unmet need within the nephrology community.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics Advances Atacicept Study in Autoimmune Kidney Diseases
- Vera Therapeutics Advances IgAN Treatment with Atacicept Study
- Vera Therapeutics Advances Atacicept Study for IgAN: Key Insights for Investors
- Vera Therapeutics initiated with a Buy at BofA
- Vera Therapeutics: Buy Rating Backed by Atacicept’s Promising Potential in IgA Nephropathy Treatment